Effect of risedronate on bone loss at discontinuation of denosumab
Purpose: The occurrence of multiple vertebral fractures was reported after denosumab discontinuation. The use of bisphosphonates following denosumab has been suggested to prevent this bone loss. The aim of our observational trial was to evaluate the ability of risedronate to prevent the bone loss re...
Main Authors: | Michel Laroche, Guillaume Couture, Adeline Ruyssen-Witrand, Arnaud Constantin, Yannick Degboé |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-12-01
|
Series: | Bone Reports |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2352187220300504 |
Similar Items
-
Failure of Oral Risedronate Therapy to Prevent Spontaneous Vertebral Fracture in a Patient Ceasing Denosumab: A Cautionary Case
by: Dahlia F Davidoff, et al.
Published: (2020-10-01) -
The Comparison of the Effect of Risedronate and Strontium Ranelate on Bone Mineral Density in Postmenopausal Women
by: Figen Yılmaz, et al.
Published: (2012-08-01) -
Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis
by: Paula Rackoff
Published: (2009-05-01) -
The Effects of Risedronate Therapy Combined With Vitamin D and Calcium on Biochemical Markers of Bone Turnover and Bone Mineral Density in Postmenopausal Osteoporosis
by: Hüsniye Koç, et al.
Published: (2004-12-01) -
Efficacy of alendronate and risedronate on bone mineral density in men with osteoporosis or osteopenia: a meta-analysis
by: Jehle, Karen, et al.
Published: (2013)